Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma

被引：3

作者：

Besic N. ^{[1
]}

Satej N. ^{[2
]}

机构：

[1] Institute of Oncology Ljubljana, 1000 Ljubljana

[2] Community Health Centre Ljubljana, 1000 Ljubljana

来源：

BMC Research Notes | / 6卷 / 1期

关键词：

Breast; Diabetes mellitus; Insulin; Oncology;

D O I：

10.1186/1756-0500-6-416

中图分类号：

学科分类号：

摘要：

Background: Recent epidemiological studies have suggested that some insulin analogues could be associated with an increased risk of cancer. The aim of this retrospective study was to examine whether patients with diabetes mellitus (DM) using insulin glargine have a higher tumor stage of breast carcinoma in comparison to patients using other types of insulin. Methods. We performed a chart review of 79 surgically treated breast carcinoma patients (mean age of 66.5 years; range 38-86 years) who were on insulin. Insulin glargine was used in 13 patients, while the other 66 patients were on other types of insulin. Clinical and histopathology characteristics of patients on glargine versus other types of insulin were compared using a chi-square test and non-parametric statistical analysis. Results: DM type 1 and DM type 2 was present in 14 and 65 patients, respectively. The mean tumor size was 2.98 cm. The TNM tumor stage at diagnosis was not higher among patients on glargine compared to patients on other types of insulin (T1/T2 85% vs. 68%, T3/T4 15% vs. 32%, p = 0.32; N1 54% vs. 58%, p = 0.80; M1 8% vs. 6%, respectively). No significant differences between both study groups (glargine vs. other types of insulin) were found in the ages of the patients, their BMI, tumor histology, grade, number of metastatic lymph nodes, hormone receptors or HER-2 status. Conclusion: We could not show that patients with DM using insulin glargine have a higher tumor stage of breast carcinoma in comparison to those using other types of insulin. © 2013 Besic and Satej; licensee BioMed Central Ltd.

引用

共 19 条

[1]

Larsson S.C., Mantzoros C.S., Wolk A., Diabetes mellitus and risk of breast cancer: A meta-analysis, International Journal of Cancer, 121, 4, pp. 856-862, (2007)

[2]

Bowker S.L., Yasui Y., Veugelers P., Johnson J.A., Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure, Diabetologia, 53, pp. 1631-1637, (2010)

[3]

Jiralerspong S., Palla S.L., Giordano S.H., Meric-Bernstam F., Liedtke C., Barnett C.M., Hsu L., Hung M.C., Hortobagyi G.N., Gonzalez-Angulo A.M., Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J Clin Oncol, 27, pp. 3297-3302, (2009)

[4]

Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 2, pp. 254-258, (2006)

[5]

Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., Sawicki P.T., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study, Diabetologia, 52, pp. 1732-1744, (2009)

[6]

Smith U., Gale E.A., Does diabetes therapy influence the risk of cancer?, Diabetologia, 52, pp. 1699-1708, (2009)

[7]

Jonasson J.M., Ljung R., Talback M., Haglund B., Gudbjornsdo ttir S., Steineck G., Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden, Diabetologia, 52, pp. 1745-1754, (2009)

[8]

Ljung R., Talback M., Haglund B., Jonasson J.M., Gudbjornsdo ttir S., Steineck G., Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation, Acta Oncol, 50, pp. 685-893, (2011)

[9]

Weinstein D., Simon M., Yehezkel E., Laron Z., Werner H., Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells, Diabetes Metab Res Rev, 25, pp. 41-49, (2009)

[10]

Mayer D., Chantelau E., Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type 1 diabetes: A pilot study on MCF-7 breast cancer cells, Arch Physiol Biochem, 116, pp. 73-78, (2010)

← 1 2 →